Share on StockTwits

VIVUS (NASDAQ:VVUS) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 36,397,351 shares, a growth of 4.1% from the April 15th total of 34,947,571 shares, reports. Approximately 36.3% of the shares of the company are short sold. Based on an average trading volume of 2,454,420 shares, the days-to-cover ratio is currently 14.8 days.

VVUS has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. cut their price target on shares of VIVUS from $8.00 to $5.00 in a research note on Tuesday, May 6th. They now have a “neutral” rating on the stock. Separately, analysts at Credit Suisse cut their price target on shares of VIVUS from $7.00 to $6.00 in a research note on Tuesday, May 6th. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of VIVUS in a research note on Thursday, April 24th. They set a “market perform” rating on the stock. Four analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. VIVUS currently has an average rating of “Hold” and an average price target of $7.64.

VIVUS (NASDAQ:VVUS) opened at 5.03 on Thursday. VIVUS has a 52-week low of $4.71 and a 52-week high of $15.62. The stock has a 50-day moving average of $5.32 and a 200-day moving average of $7.47. The company’s market cap is $519.7 million.

VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.37) by $0.22. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter last year, the company posted ($0.53) earnings per share. VIVUS’s revenue was up 792.7% compared to the same quarter last year. On average, analysts predict that VIVUS will post $-1.29 earnings per share for the current fiscal year.

VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.